Husain A Saleh1, Bo Jin, John Barnwell, Opada Alzohaili. 1. Department of Pathology, Wayne State University, Sinai Grace Hospital/Detroit Medical Center, Detroit, Michigan, USA. hsaleh@dmc.org
Abstract
BACKGROUND: Thyroid nodules are common among adults though only a small percentage is malignant, which can histologically mimic benign nodules. Accurate diagnosis of these thyroid nodules is critical for the proper clinical management. METHODS: We investigated immunoexpression in 98 surgically removed benign thyroid nodules including 52 hyperplastic nodules (HN) and 46 follicular/Hurthle cell adenomas (FA), and 54 malignant tumors including 22 follicular carcinoma (FC), 20 classic papillary carcinoma (PTC), and 12 follicular variant papillary carcinoma (FVPC). RESULTS: The staining results showed that malignant tumors express galectin-3, HBME-1, CK19 and Ret oncoprotein significantly more than benign nodules. The sensitivity of these markers for the distinction between benign and malignant lesions ranged from 83.3% to 87%. The sensitivity of two-marker panels was not significantly different. Immunoexpression was usually diffuse and strong in malignant tumors, and focal and weak in the benign lesions. CONCLUSION: Our findings indicate that these immunomarkers are significantly more expressed in malignant tumors compared to benign lesions and may be of additional diagnostic value when combined with routine histology.
BACKGROUND: Thyroid nodules are common among adults though only a small percentage is malignant, which can histologically mimic benign nodules. Accurate diagnosis of these thyroid nodules is critical for the proper clinical management. METHODS: We investigated immunoexpression in 98 surgically removed benign thyroid nodules including 52 hyperplastic nodules (HN) and 46 follicular/Hurthle cell adenomas (FA), and 54 malignant tumors including 22 follicular carcinoma (FC), 20 classic papillary carcinoma (PTC), and 12 follicular variant papillary carcinoma (FVPC). RESULTS: The staining results showed that malignant tumors express galectin-3, HBME-1, CK19 and Ret oncoprotein significantly more than benign nodules. The sensitivity of these markers for the distinction between benign and malignant lesions ranged from 83.3% to 87%. The sensitivity of two-marker panels was not significantly different. Immunoexpression was usually diffuse and strong in malignant tumors, and focal and weak in the benign lesions. CONCLUSION: Our findings indicate that these immunomarkers are significantly more expressed in malignant tumors compared to benign lesions and may be of additional diagnostic value when combined with routine histology.
Authors: P S de Matos; A P Ferreira; F de Oliveira Facuri; L V M Assumpção; K Metze; L S Ward Journal: Histopathology Date: 2005-10 Impact factor: 5.087
Authors: Katie B Weber; Kenneth R Shroyer; David E Heinz; Samia Nawaz; M Sherif Said; Bryan R Haugen Journal: Am J Clin Pathol Date: 2004-10 Impact factor: 2.493
Authors: Tijana M Isic Dencic; Svetlana B Savin; Sonja A Selemetjev; Svetlana D Paskas; Vladan R Zivaljevic; Vesna D Bozic; Dubravka S Cvejic Journal: Pathol Oncol Res Date: 2015-01-11 Impact factor: 3.201